Company intelligence / Profile preview

Advanomics

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Advanomics is developing novel anticancer drugs targeting DNA topoisomerase II using carbon-difluoride chemistry, with the lead compound Adva-27a currently at the IND-enabling/preclinical stage; it also explores mRNA-based cancer therapies, with published in vitro activity against multidrug resistant cancer cells[1][3][5].

Therapeutic areas: Oncology
Modalities: Small moleculemRNA-based drugs
Industry: Biotech

Partnerships

Jewish General Hospital, Montreal (clinical trial site for Adva-27a Phase I)Institut National des Sciences Appliquées (originated Adva-27a patents)

Beyond the preview

Go deeper on Advanomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanomics.

Explore the full profile